LIN28B Polyclonal Antibody

• Background:

  Acts as a suppressor of microRNA (miRNA) biogenesis by specifically binding the precursor let-7 (pre-let-7), a miRNA precursor. Acts by binding pre-let-7 and recruiting ZCCHC11/TUT4 uridylyltransferase, leading to the terminal uridylation of pre-let-7. Uridylated pre-let-7 miRNAs fail to be processed by Dicer and undergo degradation. Specifically recognizes the 5'-GGAG-3' motif in the terminal loop of pre-let-7. Also recognizes and binds non pre-let-7 pre-miRNAs that contain the 5'-GGAG-3' motif in the terminal loop, leading to their terminal uridylation and subsequent degradation. Mediates MYC-mediated let-7 repression. Isoform 1, when overexpressed, stimulates growth of the breast adenocarcinoma cell line MCF-7. Isoform 2 has no effect on cell growth.

• Synonyms:

  Lin28B; CSDD 2; CSDD2; FLJ16517; Lin 28 homolog B C. elegans; Lin 28.2; Lin-28B; LIN28B; LN28B_HUMAN; Protein lin-28 homolog B; Protein lin-28 homolog A, Lin-28A, Zinc finger CCHC domain-containing protein 1.

• Gene ID:

  389421, 79727

• Swiss Prot:

  Q6ZN17, Q9H9Z2

• Cellular Locus:

  Cytoplasm, Nucleus

• Host:

  Rabbit

• Cross Reactivity:

  Human, Rat

• Immunogen:

  65-160/250

• Target:

  LIN28B

• Clonality:

  Polyclonal

• Isotype:

  IgG

• Conjugation:

  Unconjugated

• Source:

  KLH conjugated synthetic peptide derived from human Lin-28B

• Applications:

  WB, ELISA, IHC-P, IHC-F, IF (IHC-P), IF (IHC-F), IF (ICC)

• Purification:

  Purified by Protein A.

• Concentration:

  1µg/µl

• Dilution:

  WB (1:300-5000), ELISA (1:500-1000), IHC-P (1:200-400), IHC-F (1:100-500), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)

• Buffer:

  0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

• Modification:

  Unmodified

• Storage Conditions:

  Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

• Gene ID URL:

  389421, 79727

• Predicted Cross Reactivity:

  Mouse, Cow, Sheep, Pig, Horse, Chicken, Rabbit